Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 2 years 24 weeks ago

Daily aspirin linked to higher risk in men

Thu, 05/03/2018 - 12:00
Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. Women, however, do not have an increased risk in this large patient population. The study was published April 27 in the Journal of the American Academy of Dermatology.
Categories: Category 2

New leads on treating dementia and Alzheimer's

Thu, 05/03/2018 - 10:00
A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to cause dementia and Alzheimer's have failed. The study has opened the way for potential new treatments with existing drugs. Published online in the journal Human Molecular Genetics, the researchers assembled evidence from a wide range of human studies and animal models of dementia-related diseases to show that inflammation is a major cause, not just a consequence.
Categories: Category 2

SMi presents the 9th Conference on Biosimilars & Biobetters

Wed, 05/02/2018 - 12:00
26 - 27 September 2018, London, UK.
The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. Following the success of the previous events in both London and the US, Biosimilars and Biobetters UK 2018 will deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
Categories: Category 2

Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes

Wed, 05/02/2018 - 10:00
Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes. Diabetes is a global epidemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy; very low levels of blood glucose can lead to cognitive decline, cardiovascular events and even death.
Categories: Category 2

Analysis links US government global health R&D funding to jobs, economic benefits across states

Tue, 05/01/2018 - 12:00
The Trump Administration's proposal to slash funding to fight global health threats like malaria, Ebola, and HIV/AIDS could cost states thousands of jobs and millions of dollars in economic investment and put the health of residents at risk, according to a new state-by-state analysis released today on Capitol Hill by the Global Health Technologies Coalition (GHTC). This first-of-its-kind analysis quantifies how federal funding to create vaccines and treatments to combat deadly global diseases also benefits American states.
Categories: Category 2

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Tue, 05/01/2018 - 10:00
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Categories: Category 2

Not enough women included in some heart disease clinical trials

Mon, 04/30/2018 - 12:00
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
Categories: Category 2

Roche reports a strong start in 2018

Mon, 04/30/2018 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division increased 7% to CHF 10.7 billion. A key growth driver was Ocrevus, used to treat two forms of multiple sclerosis. It continued its strong growth in the US and was launched in Europe and additional countries worldwide during the first quarter.
Categories: Category 2

A potential new weapon in the addiction battle: FDA-approved diabetes and obesity drugs

Fri, 04/27/2018 - 10:00
Cocaine and other drugs of abuse hijack the natural reward circuits in the brain. In part, that's why it's so hard to quit using these substances. Moreover, relapse rates hover between 40 and 60 percent, similar to rates for other chronic conditions like hypertension and Type 1 diabetes. University of Pennsylvania behavioral pharmacologist and neuroscientist Heath Schmidt studies how long-term exposure to drugs such as cocaine, nicotine, and prescription opioids affects the brain and how these changes promote relapse in someone who has kicked the habit.
Categories: Category 2

SMi presents the 13th Conference on ADMET

Thu, 04/26/2018 - 12:00
9 - 10 July 2018, London, UK.
Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.
Categories: Category 2

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Thu, 04/26/2018 - 10:00
Family-owned pharmaceutical company Boehringer Ingelheim has presented its latest pipeline updates at a Research & Development press conference entitled 'Transcending Disease Boundaries', at its global headquarters in Ingelheim, Germany. The company's R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted).
Categories: Category 2

Rabies trick could help treat Parkinson's disease

Wed, 04/25/2018 - 12:00
The rabies virus wreaks havoc on the brain, triggering psychosis and death. To get where it needs to go, the virus must first trick the nervous system and cross the blood brain barrier - a process that makes it of interest in drug design. Now, scientists report in ACS Nano a way to exploit the rabies virus machinery to deliver a Parkinson's disease medication directly to the brain.
Categories: Category 2

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

Wed, 04/25/2018 - 10:00
Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments.
Categories: Category 2

Artificial leaf as mini-factory for medicine

Tue, 04/24/2018 - 12:00
Using sunlight for sustainable and cheap production of, for example, medicines. The 'mini-factory' in the form of a leaf that chemical engineers from Eindhoven University of Technology presented in 2016 showed that it is possible. Now the researchers have come with an improved version: their 'mini-factory' is now able to keep production at the same level, irrespective of the variation in sunlight due to cloudiness or time of the day.
Categories: Category 2

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis

Tue, 04/24/2018 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration.
Categories: Category 2

Spider venom to treat paralysis

Mon, 04/23/2018 - 12:00
A team of Russian scientists together with foreign colleagues found out that the venom of crab spider Heriaeus melloteei may be used as a basis for developing treatment against hypokalemic periodic paralysis. This disease is caused by genetic mutation that leads to the occurrence of the so-called ω-currents or leakage currents via voltage-gated ion channels Nav1.4 in skeletal muscles.
Categories: Category 2

Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy

Mon, 04/23/2018 - 10:00
Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
Categories: Category 2
  • Professionalism.
    We are specialists in this field and like our activity, so we can guarantee the quality of our work.
  • Competitiveness.
    Individual solutions for a competitive price.
  • Confidentiality.
    We appreciate the cooperation, maintain confidentiality and seek for a long-term partnership